Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study

被引:12
|
作者
Onjukka, Eva [1 ,2 ]
Mercke, Claes [2 ,3 ]
Bjorgvinsson, Einar [3 ]
Embring, Anna [2 ,3 ]
Berglund, Anders [4 ]
Alexandersson von Dobeln, Gabriella [3 ]
Friesland, Signe [2 ,3 ]
Gagliardi, Giovanna [1 ]
Lenneby Helleday, Clara [3 ]
Sjodin, Helena [3 ]
Lax, Ingmar [1 ]
机构
[1] Karolinska Univ Hosp, Med Radiat Phys & Nucl Med, Stockholm, Sweden
[2] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[3] Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden
[4] Epistat Epidemiol & Stat Consulting, Uppsala, Sweden
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
xerostomia; head and neck cancer; cox regression; nomogram; registry analysis; PATIENT-RATED XEROSTOMIA; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; STICKY SALIVA; NTCP MODELS; GLANDS; IMPACT;
D O I
10.3389/fonc.2020.01647
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim Data from a local quality registry are used to model the risk of late xerostomia after radiotherapy for head and neck cancer (HNC), based on dosimetric- and clinical variables. Strengths and weaknesses of using quality registry data are explored. Methods HNC patients treated with radiotherapy at the Karolinska University hospital are entered into a quality registry at routine follow up, recording morbidity according to a modified RTOG/LENT-SOMA scale. Other recorded parameters are performance status, age, gender, tumor location, tumor stage, smoking status, chemotherapy and radiotherapy data, including prescribed dose and organ-at-risk (OAR) dose. Most patients are entered at several time points, but at variable times after treatment. Xerostomia was modeled based on follow-up data from January 2014 to October 2018, resulting in 753 patients. Two endpoints were considered: maximum grade >= 2 (XERG >= 2) or grade >= 3 (XERG >= 3) late xerostomia. Univariate Cox regression was used to select variables for two multivariate models for each endpoint, one based on the mean dose to the total parotid volume (D-tot) and one based on the mean dose to the contralateral parotid (D-contra). Cox regression allows the estimation of the risk of xerostomia at different time points; models were presented visually as nomograms estimating the risk at 9, 12, and 24 months respectively. Results The toxicity rates were 366/753 (49%) for XER(G >= 2)and 40/753 (5.3%) for XERG >= 3. The multivariate models included several variables for XERG >= 2, and dose, concomitant chemotherapy and age were included for XERG >= 3. Induction chemotherapy and an increased number of fractions per week were associated with a lower risk of XERG >= 2. However, since the causality of these relationships have limited support from previous studies, alternative models without these variables were also presented. The models based on the mean dose to the total parotid volume and the contralateral parotid alone were very similar. Conclusion Late xerostomia after radiotherapy can be modeled with reasonable predictive power based on registry data; models are presented for different endpoints highly relevant in clinical practice. However, the risk of modeling indirect relationships, given the unavoidably heterogeneous registry data, needs to be carefully considered in the interpretation of the results.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] The efficacy of Xialine® in patients with xerostomia resulting from radiotherapy for head and neck cancer:: a pilot-study
    Jellema, AP
    Langendijk, H
    Bergenhenegouwen, L
    van der Reijden, W
    Leemans, R
    Smeele, L
    Slotman, BJ
    RADIOTHERAPY AND ONCOLOGY, 2001, 59 (02) : 157 - 160
  • [22] Changes in xerostomia quality of life years after radiotherapy for head and neck cancer: Does time heal this wound?
    Schoenfeld, G.
    Amdur, R. J.
    Morris, C. G.
    Mendenhall, W. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S411 - S412
  • [23] Hypothyroidism after radiotherapy of head and neck cancer
    Bernat, Ladislav
    Hrusak, Daniel
    JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2014, 42 (04) : 356 - 361
  • [24] Hypothyroidism after radiotherapy for head and neck cancer
    Garcia-Serra, AM
    Amdur, RJ
    Hinerman, RW
    Mazzaferri, E
    Morris, CG
    Mendenhall, WM
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S499 - S499
  • [25] Low-level laser therapy for xerostomia control after head and neck radiotherapy
    Seabra, Sofia B.
    de Oliveira, Matheus S.
    Medeiros, Yuri de L.
    de S Chandretti, Paula Carolina
    Vilela, Eduardo M.
    REVISTA PORTUGUESA DE ESTOMATOLOGIA MEDICINA DENTARIA E CIRURGIA MAXILOFACIAL, 2021, 62 (03): : 176 - 180
  • [26] Xerostomia after radiotherapy in the head&neck area: Long-term observations
    Messmer, Marc-Benjamin
    Thomsen, Andreas
    Kirste, Simon
    Becker, Gerhild
    Momm, Felix
    RADIOTHERAPY AND ONCOLOGY, 2011, 98 (01) : 48 - 50
  • [27] The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer.
    Patni, N
    Patni, S
    Bapna, A
    Somani, N
    Gupta, A
    Ratnam, BV
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 505S - 505S
  • [28] Matched case-control study of quality of life and xerostomia after intensity modulated or standard radiotherapy for head and neck cancer.
    Murdoch-Kinch, CA
    Jabbari, S
    Kim, HM
    Feng, M
    Lin, A
    Tsien, C
    Elshaikh, M
    Terrell, JE
    Eisbruch, A
    JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (02) : S400 - S400
  • [29] Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients
    Junior, Gilberto de Castro
    Federico, Miriam Hatsue Honda
    CURRENT OPINION IN ONCOLOGY, 2006, 18 (03) : 266 - 270
  • [30] Risk model for dysphagia and xerostomia prediction in head and neck cancer patients treated by radiotherapy
    Teguh, D. N.
    Levendag, P. C.
    Ghidey, W.
    Montfort, K.
    Kwa, S. L. S.
    ORAL ONCOLOGY, 2011, 47 : S83 - S83